| P2093 | author name string | Antony Loebel | |
| | Ilise Lombardo | |
| | Kathleen Ice | |
| | Lewis Warrington | |
| P2860 | cites work | The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers | Q24564994 |
| | The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers | Q24564995 |
| | Antipsychotic-induced weight gain: a comprehensive research synthesis | Q28146256 |
| | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| | Ziprasidone decreases cortisol excretion in healthy subjects | Q30498400 |
| | Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic | Q33181383 |
| | Pharmacological profile of neuroleptics at human monoamine transporters | Q33857930 |
| | The pharmacology of weight gain with antipsychotics. | Q34247435 |
| | Consensus development conference on antipsychotic drugs and obesity and diabetes | Q34293049 |
| | Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity | Q34295794 |
| | Ziprasidone metabolism, aldehyde oxidase, and clinical implications | Q34534880 |
| | Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia | Q34583697 |
| | Ziprasidone: the fifth atypical antipsychotic | Q34615595 |
| | Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes | Q35115551 |
| | Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania | Q35271301 |
| | Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. | Q35777332 |
| | The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid | Q36055470 |
| | The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function | Q36055486 |
| | Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers | Q36055492 |
| | The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function | Q36055500 |
| | Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers | Q36055505 |
| | Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. | Q36068732 |
| | Ziprasidone: a novel psychotropic with unique properties | Q36107060 |
| | Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? | Q36183110 |
| | Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. | Q36432689 |
| | Economics of atypical antipsychotics in bipolar disorder: a review of the literature | Q36519345 |
| | Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. | Q36890574 |
| | Suicidality in patients with pure and depressive mania | Q40692924 |
| | Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile | Q40785107 |
| | Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of 'schizophrenic' symptoms in the light of current research | Q40919104 |
| | Mania, psychosis, and antipsychotics. | Q40984812 |
| | Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions | Q41613849 |
| | Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers | Q41614070 |
| | The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. | Q42672684 |
| | Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 |
| | Antipsychotic-induced type 2 diabetes: evidence from a large health plan database | Q44288625 |
| | Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 |
| | Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. | Q44446772 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Fatal olanzapine-induced hyperglycemic ketoacidosis | Q44913346 |
| | Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder | Q45091260 |
| | Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial | Q46596821 |
| | Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone | Q47279555 |
| | Qualitative differences in manic symptoms during mixed versus pure mania | Q48716538 |
| | Bipolar I: A Five-Year Prospective Follow-up | Q60447096 |
| | Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans | Q73513695 |
| | Association of recurrent suicidal ideation with nonremission from acute mixed mania | Q77646685 |
| | Bipolar disorder | Q80392074 |
| | Ziprasidone in bipolar disorder | Q83866936 |
| | Practice guideline for the treatment of patients with bipolar disorder (revision) | Q95789383 |
| P433 | issue | 10 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 835-849 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder | |
| P478 | volume | 21 | |